Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Leading USA based genetic testing brand officially enters the Indian market
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The Product will be manufactured at the company's facility in Bengaluru
Subscribe To Our Newsletter & Stay Updated
